TY - JOUR
T1 - The Abbreviated Methacholine Challenge Test is Safe for Children
AU - Hevroni, Avigdor
AU - Nemet, Shay
AU - Ringel, Amit
AU - Boursheh, Laurice
AU - Handler, Nitay Alter
AU - Bar-Yishay, Ephraim
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Objective: To evaluate the safety of an abbreviated methacholine challenge test (MCT) protocol in children. Study design: This prospective, observational study enrolled children aged 6 through 18 years referred for the MCT. The abbreviated protocol was initiated with a methacholine dose of 0.03 mg/ml and escalated in fourfold increments, unless the forced expiratory volume at 1 second decline exceeded 10%, at which point the next dose was only doubled. The safety of this abbreviated approach was assessed by monitoring adverse events, and specifically, decreases in forced expiratory volume at 1 second over 40%, hypoxemia, or uncontrollable cough. The number of methacholine doses and test duration were recorded and compared with estimated outcomes derived from the full-length MCT protocol. Results: One hundred twelve participants, aged 13.7 years (±3.3), successfully completed the protocol. Fifty-seven (51%) presented a positive MCT response. No significant clinical adverse events were observed. Of all participants, 2.7% exhibited an exaggerated response, in line with previously reported findings for the full-length protocol. The abbreviated approach resulted in an estimated average time-savings of 18:19 minutes per participant, thus reducing test length by 22:47 minutes for a negative MCT and by 14:34 minutes for a positive outcome. Conclusions: This abbreviated MCT protocol is safe for children and effectively shortens the duration of the MCT.
AB - Objective: To evaluate the safety of an abbreviated methacholine challenge test (MCT) protocol in children. Study design: This prospective, observational study enrolled children aged 6 through 18 years referred for the MCT. The abbreviated protocol was initiated with a methacholine dose of 0.03 mg/ml and escalated in fourfold increments, unless the forced expiratory volume at 1 second decline exceeded 10%, at which point the next dose was only doubled. The safety of this abbreviated approach was assessed by monitoring adverse events, and specifically, decreases in forced expiratory volume at 1 second over 40%, hypoxemia, or uncontrollable cough. The number of methacholine doses and test duration were recorded and compared with estimated outcomes derived from the full-length MCT protocol. Results: One hundred twelve participants, aged 13.7 years (±3.3), successfully completed the protocol. Fifty-seven (51%) presented a positive MCT response. No significant clinical adverse events were observed. Of all participants, 2.7% exhibited an exaggerated response, in line with previously reported findings for the full-length protocol. The abbreviated approach resulted in an estimated average time-savings of 18:19 minutes per participant, thus reducing test length by 22:47 minutes for a negative MCT and by 14:34 minutes for a positive outcome. Conclusions: This abbreviated MCT protocol is safe for children and effectively shortens the duration of the MCT.
KW - abbreviated MCT protocol
KW - bronchial hyperresponsiveness
KW - forced expiratory volume at 1 second (FEV)
KW - methacholine challenge test (MCT)
UR - http://www.scopus.com/inward/record.url?scp=85204034400&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2024.114250
DO - 10.1016/j.jpeds.2024.114250
M3 - Article
C2 - 39181318
AN - SCOPUS:85204034400
SN - 0022-3476
VL - 276
JO - Journal of Pediatrics
JF - Journal of Pediatrics
M1 - 114250
ER -